Assembly Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Assembly Biosciences's estimated annual revenue is currently $7.3M per year.
- Assembly Biosciences received $86.2M in venture funding in March 2015.
- Assembly Biosciences's estimated revenue per employee is $86,786
- Assembly Biosciences's total funding is $2.5M.
- Assembly Biosciences's current valuation is $90.7M. (January 2022)
Employee Data
- Assembly Biosciences has 84 Employees.
- Assembly Biosciences grew their employee count by -12% last year.
Assembly Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Assembly Biosciences?
Assembly Biosciences, Inc. (Nasdaq: ASMB) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome. Assembly is developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly's HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit www.assemblybio.com. Company headquarters in Carmel, IN and San Francisco, CA.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$2.5M
Total Funding
84
Number of Employees
$7.3M
Revenue (est)
-12%
Employee Growth %
$90.7M
Valuation
N/A
Accelerator
Assembly Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Regulatory Affairs And Quality Assurance | Reveal Email/Phone |
2 | Head Microbiome Clinical Development | Reveal Email/Phone |
3 | Sr. Manager, HR Operations | Reveal Email/Phone |
4 | Sr Director Regulatory Affairs | Reveal Email/Phone |
5 | Executive Director, Clinical Development | Reveal Email/Phone |
6 | VP Manufacturing | Reveal Email/Phone |
7 | Executive Director, Accounting & Treasury | Reveal Email/Phone |
8 | Executive Director, Informatics | Reveal Email/Phone |
9 | VP, General Counsel and Corporate Secretary | Reveal Email/Phone |
10 | Director Preclinical Development | Reveal Email/Phone |
Assembly Biosciences News
According to Zacks, analysts expect that Assembly Biosciences will report full year earnings of ($2.00) per share for the current fiscal year,...
... senior director of licensing and technology transactions at Ultragenyx Pharmaceutical Inc.; Assembly Biosciences Inc. CFO Michael Samar;...
Truist Securities Maintains Buy on Assembly Biosciences, Lowers Price Target to $12. by Benzinga Newsdesk, Benzinga Staff Writer.
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.5M | 84 | 5% | N/A |
#2 | $12.2M | 84 | -24% | $5.8M |
#3 | $12.2M | 84 | -14% | $18.9M |
#4 | $19.1M | 84 | 56% | N/A |
#5 | $27.3M | 84 | -5% | N/A |
Assembly Biosciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-20 | $86.2M | Undisclosed | Credit Suisse | Article |
Assembly Biosciences Executives
| Name | Title |
|---|---|
| Jason Okazaki | Chief Executive Officer |
| Michele Anderson | Chief Development Officer |
| Luisa Stamm | Chief Medical Officer |
| William Delaney | Chief Scientific Officer |
| Jeff Woollard | Chief Executive Officer & President, Director |
| Jennifer Troia | Chief Human Resources Officer |
| Suzette DeVito | EXECUTIVE ASSISTANT TO THE CHIEF EXECUTIVE OFFICER |
| William Delaney | Chief Scientific Officer |
| Nicole White | Chief Manufacturing Officer |
| John McHutchison | CEO & Director |
| Eric Ruby | Vice President, Regulatory Affairs And Quality Assurance |
| Katie Kitrinos | Vice President, Clinical Virology |
| Steven Knox | Senior Vice President, Clinical Development |
| Carl Henrik Enell | Senior Vice President, Corporate Development |
| Wayne Herber | Vice President Manufacturing |
| David Houck | SVP Manufacturing and Program Management at Assembly Bio |
| Qi Huang | Vice President, Virology Discovery |
| Julie Ma | Vice President of Biometrics |
| Jeff Woollard | Chief Executive Officer & President, Director |
| George Grandolfi | Vice President, Drug Product Development |
| Nicole White | SVP, Pharmaceutical Development & Manufacturing |